EGFR and lung carcinoma: Arasada et al.21 first reported that the EGFR inhibition by erlotinib treatment is able to activate Notch signaling in human lung cancer, resulting in an enriched stem cell-like populations in a Notch3, but not Notch1-dependent manner.